KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Gains from Sales and Divestitures (2021 - 2025)

Historic Gains from Sales and Divestitures for LifeMD (LFMD) over the last 5 years, with Q3 2025 value amounting to $1.9 million.

  • LifeMD's Gains from Sales and Divestitures rose 4707.92% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 4707.92%. This contributed to the annual value of $1.5 million for FY2024, which is 11555.65% up from last year.
  • As of Q3 2025, LifeMD's Gains from Sales and Divestitures stood at $1.9 million, which was up 4707.92% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, LifeMD's Gains from Sales and Divestitures ranged from a high of $1.9 million in Q3 2025 and a low of $26875.0 during Q2 2021
  • Its 5-year average for Gains from Sales and Divestitures is $667067.3, with a median of $512312.5 in 2022.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 7811.36% in 2023, then surged by 59293.87% in 2024.
  • LifeMD's Gains from Sales and Divestitures (Quarter) stood at $77875.0 in 2021, then skyrocketed by 127.45% to $177125.0 in 2022, then skyrocketed by 280.88% to $674625.0 in 2023, then skyrocketed by 115.56% to $1.5 million in 2024, then rose by 29.99% to $1.9 million in 2025.
  • Its Gains from Sales and Divestitures was $1.9 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.2 million in Q1 2025.